Cargando…

pK(a) of opioid ligands as a discriminating factor for side effects

The non-selective activation of central and peripheral opioid receptors is a major shortcoming of currently available opioids. Targeting peripheral opioid receptors is a promising strategy to preclude side effects. Recently, we showed that fentanyl-derived μ-opioid receptor (MOR) agonists with reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Vecchio, Giovanna, Labuz, Dominika, Temp, Julia, Seitz, Viola, Kloner, Michael, Negrete, Roger, Rodriguez-Gaztelumendi, Antonio, Weber, Marcus, Machelska, Halina, Stein, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920366/
https://www.ncbi.nlm.nih.gov/pubmed/31852967
http://dx.doi.org/10.1038/s41598-019-55886-1
Descripción
Sumario:The non-selective activation of central and peripheral opioid receptors is a major shortcoming of currently available opioids. Targeting peripheral opioid receptors is a promising strategy to preclude side effects. Recently, we showed that fentanyl-derived μ-opioid receptor (MOR) agonists with reduced acid dissociation constants (pK(a)) due to introducing single fluorine atoms produced injury-restricted antinociception in rat models of inflammatory, postoperative and neuropathic pain. Here, we report that a new double-fluorinated compound (FF6) and fentanyl show similar pK(a), MOR affinity and [(35)S]-GTPγS binding at low and physiological pH values. In vivo, FF6 produced antinociception in injured and non-injured tissue, and induced sedation and constipation. The comparison of several fentanyl derivatives revealed a correlation between pK(a) values and pH-dependent MOR activation, antinociception and side effects. An opioid ligand’s pK(a) value may be used as discriminating factor to design safer analgesics.